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Abstract 
Background: Stereotactic radiosurgery (SRS) has been recognized as a first‑line treatment option for small to moder‑
ate sized vestibular schwannoma (VS). Our aim is to evaluate the impact of SRS doses and other patient and disease 
characteristics on vestibular function in patients with VS.
Methods: Data on VS patients treated with single‑fraction SRS to 12 Gy were retrospectively reviewed. No dose 
constraints were given to the vestibule during optimization in treatment planning. Patient and tumor characteristics, 
pre‑ and post‑SRS vestibular examination results and patient‑reported dizziness were assessed from patient records.
Results: Fifty‑three patients were analyzed. Median follow‑up was 32 months (range, 6–79). The median minimum, 
mean and maximum vestibular doses were 2.6 ± 1.6 Gy, 6.7 ± 2.8 Gy, and 11 ± 3.6 Gy, respectively. On univariate 
analysis, Koos grade (p = 0.04; OR: 3.45; 95% CI 1.01–11.81), tumor volume (median 6.1  cm3; range, 0.8–38; p = 0.01; OR: 
4.85; 95% CI 1.43–16.49), presence of pre‑SRS dizziness (p = 0.02; OR: 3.98; 95% CI 1.19–13.24) and minimum vestibu‑
lar dose (p = 0.033; OR: 1.55; 95% CI 1.03–2.32) showed a significant association with patient‑reported dizziness. On 
multivariate analysis, minimum vestibular dose remained significant (p = 0.02; OR: 1.75; 95% CI 1.05–2.89). Patients 
with improved caloric function had received significantly lower mean (1.5 ± 0.7 Gy, p = 0.01) and maximum doses 
(4 ± 1.5 Gy, p = 0.01) to the vestibule.
Conclusions: Our results reveal that 5 Gy and above minimum vestibular doses significantly worsened dizziness. 
Additionally, mean and maximum doses received by the vestibule were significantly lower in patients who had 
improved caloric function. Further investigations are needed to determine dose‑volume parameters and their effects 
on vestibular toxicity.
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Background
Sterotactic radiosurgery (SRS) is considered as a first-line 
treatment for small or moderate sized vestibular schwan-
nomas (VS) [1–4]. However, its impact on vestibular 
function and perception of dizziness depending on the 
applied dose remains uninvestigated. Despite their rela-
tively slow growth, some patients with VS present with 
symptoms including hearing loss (about 90%), tinnitus 
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(65–75%), impaired balance (about 60%) and neuropa-
thies of the cranial nerves (4–8%) [5]. These presenting 
symptoms and/or continued expansion of the tumor 
may lead clinicians to seek for the optimal management 
option. The toxicity profile of each intervention, along 
with the patient and tumor characteristics, should be 
considered in decision-making on management [6, 7].
Much research has been published on post-treatment 
morbidity related to radiotherapy [8–10]. So far, most 
of the studies analyzing treatment toxicity have focused 
primarily on hearing impairment and cranial nerve dam-
age. The mechanism of immediate and delayed hearing 
deterioration has been scrutinized [11, 12]. In relation 
to hearing loss, the radiation dose to the cochlea and its 
components (e.g. modiolus), to the vestibulocochlear 
nerve, and the cochlear nucleus in the brain has been 
measured leading to dose-volume recommendations 
[13–15]. Cranial nerve outcomes have been reported 
and optimal marginal doses for better nerve preserva-
tion have been proposed [9, 16]. However, data on the 
effects of radiotherapy, especially SRS, on dizziness are 
scarce. Vestibular toxicity can be defined according to the 
common terminology criteria for adverse events version 
5.0 as a disorder characterized by dizziness, imbalance, 
nausea, and vision problems [17]. Dizziness is the sensa-
tion of disturbed or impaired spatial orientation without 
a false or distorted sense of motion [18]. It could be the 
main presenting symptom and can be extremely disturb-
ing with deterioration on the patient’s quality of life [19, 
20]. Previous studies showed that after SRS, about 17% of 
patients developed transient dizziness and up to 3% had 
continuous (chronic) dizziness [21, 22]. Given that ves-
tibular toxicity is a strong predictor of the quality of life 
of VS patients, research evaluating this parameter would 
contribute to preserving health-related well-being [23, 
24].
To the best of our knowledge, none of the published 
studies has shown statistically relevant results relating 
the radiotherapy dose to the vestibule to changes in dizzi-
ness after SRS. The primary objective of the current study 
was to evaluate the impact of SRS doses and other patient 
and disease characteristics on dizziness in patients with 
VS. Such information should help to define vestibular 
dosimetric parameters in patients treated with SRS and 
may assist in determining the vestibular dosimetry and 
its relationship to dizziness.
Methods
Patient selection
With the approval of the regional ethics committee, 
patients who received SRS for VS between 2010 and 2016 
were retrospectively evaluated.
Fifty-three patients met the inclusion criteria of receiv-
ing single-fraction SRS for unilateral, sporadic VS. 
Patients < 18  years old, with neurofibromatosis type 2, 
those who had undergone prior radiotherapy or micro-
surgery, and patients who were treated with multi-frac-
tionation schemes were excluded from the study. Clinical 
and radiosurgical data were collected from patient charts 
and medical follow-up notes, including: age, sex, tumor 
location and morphology, pre-SRS growth, tumor vol-
ume, Koos grade, pre-SRS dizziness/tinnitus, target and 
vestibule doses (minimum, mean and maximum), post-
SRS transient volume expansion (defined as volume 
growth followed by shrinkage to the pre-SRS volume or 
less), post-SRS tumor necrosis (detected by sequential 
magnetic resonance (MR) images) and objective neu-
rootological examination.
Radiosurgical procedure
All patients received treatment either with a Linac 
(Novalis TX, BrainLAB AG, Feldkirchen, Germany; Var-
ian Medical Systems, Palo Alto, CA, USA) or robotic-
based (Cyberknife, Accuray, Sunnyvale, California) 
radiosurgical system. Patients were immobilized in the 
supine position using a commercial stereotactic mask 
fixation system. Thin-sliced (0.75 mm) computed tomog-
raphy (CT) images without contrast were obtained. Con-
trast-enhanced T1- and T2-weighted high-resolution MR 
images (1  mm) and, when available, three-dimensional 
constructive interference in steady-state (3D-CISS) 
sequence images were registered with CT images for 
target delineation. After tumor delineation by a radia-
tion oncologist, a medical physicist planned the treat-
ment. No additional margin to the target volume was 
included for the planning target volume. A single frac-
tion of 12 Gy to the mean 78% (range, 52–90%) isodose 
line for Cyberknife treatment plans and to the mean 94% 
(range, 85–98%) isodose line for Novalis treatment plans 
was prescribed. SRS plans were generated and delivered 
using the treatment planning systems of iPlan (Novalis) 
and Multiplan (Cyberknife). The quality of the treat-
ment plans was assessed by evaluating target coverage, 
dose heterogeneity/conformity, and normal tissue dose 
tolerance, particularly cochlear dosimetry. KV imaging 
(ExacTrac, Brainlab) for Linac-based and real-time X-ray 
patient tracking (6D-Skull) for robotic-based systems 
were used for set-up verification and repositioning.
Patient follow‑up
All patients were followed up at 6  months using MR 
imaging and clinical examination and again at 1  year 
post-SRS with additional objective neurootological 
tests. Long-term assessments were performed annually. 
Vestibular testing comprised a patient history, clinical 
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neurotological and focused neurological examination 
including cranial nerves III-XII, cerebellar examination, 
stance tests (Romberg [standing > 20  s] and Unterberger 
[walking 50 steps in place without deviation > 45°]). The 
vestibular tests were consist of video-oculography includ-
ing head hanging test (Rose manoeuvre), test for sponta-
neous nystagmus at all gaze directions, smooth pursuit, 
rotatory chair examination (sinusoidal harmonic accel-
eration [SHA] test at 60  °/s chair velocity and 0.02 Hz), 
cervical vestibular evoked myogenic potentials (cVEMP, 
500-Hz tone-burst stimuli) and bithermal caloric testing. 
The degree of asymmetry in caloric testing was catego-
rized in; normal (0–25%), mild hypofunction (26–50%), 
moderate hypofunction (51–75%) and severe hypofunc-
tion (76–100%). Clinical examination and vestibular 
test results were reported pre-SRS and 1-year post-SRS. 
The results were classified as stable/improved if the 
patient maintained the same function or showed bet-
ter function, and as worse if the function deteriorated. 
Patient-reported dizziness was recorded pre-SRS and at 
6  months post-SRS. At each time point, patients were 
asked whether they experienced any form of dizziness 
(at the time of the examination, or any episode) and the 
responses were coded as a binary outcome, yes or no.
Dosimetry of the vestibule
Based on the CT and MR images for each SRS plan, the 
volume of the vestibule was defined with the assistance 
of a senior board-certified neuroradiologist specialized in 
head and neck imaging (FW). Six to ten successive axial 
slices were used for precise volume definition. Location 
of the vestibule was defined as the common junction of 
the cochlea and semi-circular canals, where internal audi-
tory canal separates cochlea from the vestibule (Fig. 1a). 
The minimum, mean, and maximum radiation doses 
received by the vestibule volume were obtained from the 
treatment planning software. Vestibule delineation was 
performed retrospectively and no dose constraints were 
given to the vestibule during plan optimization.
Statistics
A certified statistician (DL) performed the statistical 
analysis. Duration of follow-up was defined as starting 
from the day of SRS. Descriptive analyses were reported 
as mean (standard deviation), median (range) or number 
(percentage). Logistic regression was used to assess 
variables that might influence dizziness at the specified 
follow-up times. Variables with a p value < 0.1 in the uni-
variate analyses were included in the multivariate analy-
sis. The t-test was used to test the association between 
continuous variables.
A p value of < 0.05 was set as statistically significant. 
Statistical analyses were performed with IBM SPSS Sta-




The study cohort consisted of 27 male (51%) and 26 
female (49%) patients. The median follow-up duration 
was 32  months (range, 6–79  months). Table  1 summa-
rizes baseline patient and VS characteristics. Thirty-three 
patients (62%) were treated with the Novalis TX system. 
The remaining twenty patients received SRS with the 
Cyberknife system, after it was introduced in the facil-
ity in 2014. The mean age at the time of the SRS was 
60 years (range, 23–80 years). The median target volume 
was 6.18   cm3 (range, 0.8–38  cm3). Thirty-two patients 
(60%) had lower Koos grade (I–II) and 21 patients (40%) 
had higher Koos grade (III–IV). Initially, 37 patients 
(70%) had tinnitus and the same number reported dizzi-
ness. Clinical examination showed that six patients (11%) 
had spontaneous nystagmus, seven (13%) and 14 (26%) 
abnormal Romberg and Unterberger tests, respectively. 
Among vestibular tests, in 16 patients (30%) cVEMP 
responses were absent before treatment and the median 
percentage caloric weakness was 33.5% (range, 3–100%).
Dose parameters, dizziness and vestibular outcome
The mean target volume dose for the entire cohort, 
Cyberknife and Novalis delivery systems were 12.7  Gy 
(range, 11.8–17.7  Gy), 13.8 (range, 12.6–17.7  Gy) and 
12.4 Gy (range, 11.8–13.4 Gy), respectively. The median, 
minimum, mean, and maximum radiation doses deliv-
ered to the vestibule for the entire cohort were 2.6  Gy 
(range, 0.05–6.2  Gy), 6.7  Gy (range, 0.3–10.8  Gy) and 
11 Gy (range, 2–17 Gy), respectively. For the Cyberknife 
delivery system, detected vestibular doses were mini-
mum 2.9  Gy (range, 0.05–4.7  Gy), mean 5.9  Gy (range, 
0.3–9.1 Gy) and maximum 9.3 Gy (range, 2.1–17.1 Gy). 
Figure1 a Axial CT (left) and CISS images showing the volume of vestibule (red arrow, orange line). The blue arrows indicate cochlea, semi‑circular 
canals and internal auditory canal. CT computed tomography, CISS constructive interference in steady‑state. b Axial, sagittal and coronal CISS MR 
and CT images showing the volume of the cochlea (blue arrow) and vestibule (green arrow) with the different isodose lines from a treatment plan 
for Cyberknife. A dose of 12 Gy in a single fraction was prescribed to 80% isodose line and no dose constraints were given to the vestibule during 
treatment plan optimization. It is evident that cochlea is very well spared by giving it priority during plan optimization, while 70% (10.5 Gy) to 30% 
(4.5 Gy) isodose lines cover the vestibular volume
(See figure on next page.)
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For the Novalis delivery system, dose calculations on 
the vestibule were minimum 2.8  Gy (range, 0.2–6  Gy), 
mean 7.2 Gy (range, 0.5–10.8 Gy) and maximum 11.8 Gy 
(range, 2–13.7  Gy). Post-SRS, eighteen patients (34%) 
experienced transient volume expansion. In 31 patients 
(58%), radiological tumor necrosis was detected. At the 
6-month follow-up visit, 40 patients (75.5%) reported sta-
ble or improved dizziness, while in eight patients (15%), 
dizziness had worsened. There was a correlation between 
caloric testing worsening and patient reported dizziness 
worsening in three out of eight patients. No data were 
available for five patients (9.5%).
Vestibular testing at 1  year showed that results of 
video-oculography were stable/improved in 24 patients 
(45%). The median percentage caloric weakness increased 
to 76% (range, 2–100%). Twelve patients showed a stable/
improved caloric test result in relation to the categories 
regarding the degree of asymmetry, while 13 patients had 
a worsened low frequency function. Following treatment, 
cVEMP responses were present in seven patients, with a 
stable/improved response rate of 24.5%. Post-SRS tumor 
characteristics, outcome of dizziness, results of the 
clinical examination and vestibular tests, and the dose 
parameters of SRS are summarized in Table 2. Figure 1b 
represents an example case with the dose distributions in 
a Cyberknife treatment plan.
Risk factors for dizziness
Univariate analyses showed that larger target volume 
(> 6.1  cm3; p = 0.01; OR: 4.85; 95% CI 1.43–16.49), higher 
Koos grade (III–IV vs I–II; p = 0.04; OR: 3.45; 95% CI 
1.01–11.81), presence of pre-SRS dizziness (p = 0.02; 
OR: 3.98; 95% CI 1.19–13.24) and minimum dose to the 
vestibule (p = 0.03; OR: 1.55; 95% CI 1.03–2.32) were 
significantly associated with patient-reported dizziness 
after SRS (Table 3). In the subsequent multivariate analy-
ses, minimum dose to the vestibule (p = 0.02; OR: 1.75; 
95% CI 1.05–2.89) remained significantly associated with 
dizziness. Figure  2 relates various minimum dose lev-
els received by vestibule to dizziness after SRS. For the 
patients treated with a minimum dose of < 2 Gy, 2–3 Gy, 
3–4 Gy, 4–5 Gy, and > 5 Gy, dizziness rates of 40%, 25%, 
50%, 75% and 100% respectively, were found. Notably, 
all patients who received a minimum vestibular dose of 
more than 5 Gy reported dizziness after treatment.
The t test showed that patients with improved caloric 
function after SRS had received significantly lower mean 
(1.5 ± 0.7 Gy, p = 0.01) and maximum doses (4 ± 1.5 Gy, 
p = 0.01) to the vestibule than the patients who had a 
stable or worsened caloric function. Table 4 summarizes 
dosimetric parameters of the vestibule related to caloric 
function outcome. No other significant correlation could 
Table 1 Baseline patient and tumor characteristics, n = 53
cVEMP cervical vestibular evoked myogenic potentials, SRS stereotactic 
radiosurgery, ips. ipsilateral
a Values are median (range) or number (percentage)
Characteristic Valuea
Age (years) 60 (23–80)
Sex
 Male 27 (51)
 Female 26 (49)
Location
 Intra‑canalicular 10 (19)
 Extra‑canalicular 43 (81)
Cystic component 8 (15)
Target volume  (cm3) 6.18 (0.8–38)
Pre‑SRS tumor growth 36 (68)
Koos grade
 I 7 (13)
 II 26 (49)
 III 11 (21)
 IV 10 (17)
Pre‑SRS tinnitus 37 (70)
Patient‑reported dizziness 37 (70)
Clinical examination
 Spontaneous nystagmus 6 (11)
 Romberg test
  Normal 31 (58)
  Abnormal (positive) 7 (13.5)
 Unterberger test
  Normal 24 (45)
  Abnormal (positive) 14 (26.5)
 No data available 15 (28.5)
Vestibular tests
 Video‑oculography
  No spontaneous nystagmus 27 (51)
  Spontaneous nystagmus 4 (7.5)
  Pathologic smooth pursuit 7 (13)
  No data available 15 (28.5)
 Caloric ips. testing (degree of asymmetry)
  Normal (0–25%) 3 (5)
  Mild hypofunction (26–50%) 29 (55)
  Moderate hypofunction (51–75%) 2 (4)
  Severe hypfunction (76–100%) 4 (7.5)
  Percentage caloric weakness (%) 33.5 (3–100)
  No data available 15 (28.5)
 cVEMP
  Normal 8 (15)
  Absent reflex 16 (30)
  No data available 29 (55)
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be found between vestibular test results and patient, dis-
ease, or dose characteristics.
Discussion
The effectiveness of an intervention in treating a benign 
disease can be assessed, in addition to the control of the 
disease, by its impact on the patient’s daily life. Dizziness 
affects 30–65% of patients diagnosed with VS, regardless 
of the treatment modality. Patients would like to know 
whether the proposed intervention is expected to relieve 
their most significant symptoms [25]. Several studies have 
demonstrated that dizziness is a more effective predictor 
of patient-reported quality of life than other parameters 
such as hearing loss or facial neuropathy [23–25]. Cer-
tainly, more research is warranted to better understand 
the mechanism and management of the dizziness. On the 
other hand, there is no direct correlation between ves-
tibular function and dizziness perception reported in the 
literature. Dizziness perception is rather dependent on 
central vestibular compensation mechanisms. Vestibular 
compensation and adaptation starts immediately after a 
lesion on the vestibular nerve [26]. However, preserving 
or even improving vestibular function after SRS in com-
bination with vestibular physiotherapy has the potential 
to improve the quality of life of these patients [27]. Our 
study focused mainly on whether radiation doses to the 
vestibule have an impact on patient-reported dizziness 
and vestibular test results.
The European Particle Therapy Network consensus, 
published in 2018, includes recommendations on deline-
ation of radiation sensitive organs at risk and their dose 
constraints for an unbiased comparison of different radi-
ation modalities and techniques [28]. In the section on 
vestibulum and semi-circular canals, the authors noted 
that few data were available on vestibular toxicity and 
radiotherapy and emphasized the importance of prospec-
tive collection of dose-volume data and accurate toxicity 
scoring. Stavas et al. conducted one of the few studies on 
this subject. The authors studied how the vestibule dose 
might predict change in balance function and patient-
reported dizziness after SRS in a prospective observa-
tional pilot study [29]. Of the ten patients included, nine 
were treated with fractionated stereotactic radiotherapy 
(20–22  Gy in five fractions) and one with SRS (12  Gy). 
Dose volume data were obtained including mean and 
maximum dose to the vestibule and the volume of vesti-
bule receiving 5 Gy, 10 Gy and 15 Gy (V5, V10, and V15). 
Self-reported measures were evaluated with Dizziness 




 Minimum 2.6 (0.05–6.2)
 Mean 6.7 (0.3–10.8)
 Maximum 11 (2–17)
Target volume doses (Gy)
 Minimum 11.3 (6.2–12)
 Mean 12.7 (11.8–17.7)
 Maximum 13 (12.1–23)
Transient volume expansion 18 (34)
Post‑SRS tumor necrosis 31 (58)
Patient‑reported dizziness
 Stable/improved 40 (75.5)
 Worsened 8 (15)
 No data available 5 (9.5)
Clinical examination
 Spontaneous nystagmus
  Stable/improved 29 (55)
  Worsened 9 (17.5)
  No data available 15 (28.5)
 Romberg test
  Stable/improved 27 (51)
  Worsened 2 (4)
  No data available 24 (45)
 Unterberger test
  Stable/improved 19 (36)
  Worsened 10 (19)
  No data available 24 (45)
Vestibular tests
 Video‑oculography
  No spontaneous nystagmus 22 (42)
  Spontaneous nystagmus 3 (5)
  Pathologic smooth pursuit 3 (5)
  No data available 25 (48)
  Stable/improved 24 (45)
  Worsened 2 (4)
 Caloric ips. testing
  Normal (0–25%) 2 (4)
  Mild hypofunction (26–50%) 9 (17.5)
  Moderate hypofunction (51–75%) 3 (5)
  Severe hypofunction (76–100%) 11 (21)
  Percentage caloric weakness (%) 76 (2–100)
  No data available 28 (52.5)
  Stable/improved 12 (23)
  Worsened 13 (24.5)
 cVEMP
  Normal 7 (13)
  Absent reflex 14 (26)
  No data available 32 (60.5)
  Stable/improved 13 (24.5)
  Worsened 2 (4)
Table 2 (continued)
cVEMP cervical vestibular evoked myogenic potentials, SRS stereotactic 
radiosurgery, ips. ipsilateral
a Values are median (range) or number (percentage)
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Handicap Inventory (DHI). No significant associations 
or identifiable trends were found between the radiation 
dose and the change in objective or subjective vestibular 
function. A related study was presented as a poster at the 
37th European Society of Radiotherapy and Oncology 
congress by Bambery and Cameron. They investigated 
the relationship between labyrinth dose and dizziness 
in VS patients [30]. Data on 114 patients treated with 
SRS with a mean dose of 12.3  Gy were retrospectively 
reviewed. Labyrinth and vestibule were retrospectively 
contoured on all treatment plans and length of vestibu-
lar nerve treated with treatment dose measured. All 
patients completed DHI at a minimum of treatment day 
and 3  months post SRS. Similar to the study by Stavas 
et  al., no statistical correlation could be found between 
any of the dose measurements (the mean vestibule 
dose and maximum to 1   mm3 vestibule dose; labyrinth 
mean dose and maximum to 1   mm3 labyrinth dose; and 
Table 3 Association between patient, disease, and dose characteristics, and patient‑reported dizziness
Values in bold statistically significant
CI confidence interval, OR odds ratio, SRS stereotactic radiosurgery
Parameter Univariate variables Multivariate model
OR (95% CI) p value OR (95% CI) p value
Age in years (> 65 vs ≤ 65) 1.12 (0.32–3.90) 0.85
Location (intra‑ vs extra‑canalicular) 2.10 (0.46–9.64) 0.33
Cystic component (yes vs no) 1.10 (0.24–5.04) 0.89
Target volume (> vs ≤ 6.1  cm3) 4.85 (1.43–16.49) 0.01 2.84 (0.53–15.04) 0.21
Target minimum dose 0.85 (0.27–2.67) 0.80
Target mean dose 0.72 (0.23–2.24) 0.57
Target maximum dose 0.51 (0.16–1.61) 0.25
Pre‑SRS tumor growth (yes vs no) 2.02 (0.56–7.31) 0.28
Koos grade (III–IV vs I–II) 3.45 (1.01–11.81) 0.04 2.41 (0.41–14.24) 0.33
Pre‑SRS tinnitus (yes vs no) 1.33 (0.38–4.67) 0.65
Pre‑SRS dizziness (yes vs no) 3.98 (1.19–13.24) 0.02 4.15 (1.00–17.20) 0.05
Vestibule minimum dose 1.55 (1.03–2.32) 0.03 1.75 (1.05–2.89) 0.02
Vestibule mean dose 1.10 (0.89–1.35) 0.35
Vestibule maximum dose 1.01 (0.86–1.19) 0.82
Transient volume expansion (yes vs no) 1.96 (0.58–6.61) 0.27
Novalis vs Cyberknife 0.47 (0.14–1.55) 0.21
Fig. 2 Graph showing the correlation between minimum radiation dose levels to the vestibule and percentage of patients reporting dizziness
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length of nerve receiving treatment dose) and changes in 
patient-reported dizziness. In contrast, in our study the 
minimum dose of more than 5  Gy to the vestibule was 
statistically significantly associated with patient-reported 
dizziness following SRS. Additionally, mean and maxi-
mum doses received by the vestibule were significantly 
lower in patients who had improved caloric test outcome 
after SRS. We believe that our study is the first to dem-
onstrate a significant association between vestibular dose 
and dizziness.
The value of a minimum dose for an organ at risk gen-
erally does not have a clinical impact in radiotherapy plan 
evaluation. However, our findings suggest that limiting 
the minimum vestibular dose to less than 5  Gy poten-
tially results in fewer patients experiencing dizziness. In 
our cohort, no dose constraints were given to the ves-
tibule during radiation plan optimization. As a result, 
the mean and maximum doses to the vestibule are rela-
tively high and similar in all treatment plans. This may 
help explain why no correlation between dizziness and 
mean/maximum doses received by the vestibule could be 
found. Interestingly, patients receiving the lowest mean 
(1.5 ± 0.7  Gy) and maximum (4 ± 1.5  Gy) doses to the 
vestibule showed a significant improvement in caloric 
test in our analysis, although the minimum doses had no 
effect. Compared to the minimum doses of 5 Gy that had 
a potential effect on patient-reported dizziness, the mean 
and maximum doses that positively affected caloric func-
tion were much lower.
Risk factors for dizziness other than vestibular dosim-
etry in our study were consistent with those reported 
in the literature. Carlson et  al. [31] studied patients 
sporadic VS who had undergone microsurgery, SRS or 
observation. They reported that female sex, older age, 
large tumor size, and presence of dizziness or headaches 
before treatment were associated with long-term diz-
ziness. Our findings suggest that larger tumor volume 
associated with higher Koos grades and the presence of 
pre-SRS dizziness were the factors influencing patient-
reported dizziness in the univariate analysis.
The study has several limitations due to its retrospec-
tive nature. First, one of the most widely used, validated 
quality of life measurement questionnaires, DHI, was 
not available for our study. Our patient-reported meas-
urement was coded as a binary outcome, which provides 
only limited information. Second, a large amount of 
patient data was missing after treatment, which reduced 
the sample size and the statistical power. In addition, due 
to the small number of events (only eight patients expe-
rienced dizziness worsening after SRS), the effects of the 
proportional regression analysis should be interpreted 
with caution [32]. Third, we reported the early dizziness 
outcome and factors influencing it and, therefore, our 
results are limited to short term outcomes and should be 
extrapolated with care. Forth, we tested only vestibular 
function at low and middle frequencies, which are not 
completely reflecting the dynamic range of vestibular 
function in daily life. Furthermore, we did not fully assess 
all functions of the vestibule, including ocular VEMPs, 
which measure utricular function. VEMPs responses can 
often not be triggered in patients older than 60. Addi-
tionally, the measured doses did not include the semicir-
cular canals. Due to the close proximity of the vestibule 
and the ampulla, a similar dose can be presumed. Finally, 
there could be inaccuracies in iPlan RT dose for small 
field dosimetry.
Conclusions
In this study, we have demonstrated that during a SRS 
procedure for the treatment of VS, a significant dose of 
radiation is delivered to the vestibule. We found a sig-
nificant correlation between the radiation dose received 
by the vestibule during SRS for VS and the vestibular 
outcome: 5  Gy and above minimum vestibular doses 
significantly worsened dizziness following the radio-
surgical procedure. Additionally, mean and maximum 
doses received by the vestibule were significantly lower 
Table 4 Summary of dosimetric parameters of the vestibule related to caloric function outcome
Values in bold statistically significant
a T-test
b Values are mean ± standard deviation
Parameter Caloric function outcome after SRS
Stable p valuea Improved p  valuea Worsened p  valuea
No of patients 9 – 3 – 13 –
Min. dose to vestibule (Gy)b 2.6 ± 1.5 – 0.46 ± 0.2 0.06 3 ± 1.2 0.52
Mean dose to vestibule (Gy)b 6.9 ± 2.8 – 1.5 ± 0.7 0.01 6.6 ± 1.7 0.79
Max dose to vestibule (Gy)b 11.3 ± 3.7 – 4 ± 1.5 0.01 10.2 ± 2.1 0.41
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in patients who had improved caloric function. Further 
investigations are necessary to validate our findings. We 
plan to repeat this analysis on a new set of patients using 
a prospective study design and collecting the dose-vol-
ume data of the labyrinth with a precise assessment of 
the vestibular toxicity.
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